Propafenone
Propafenone (propafenone) is a small molecule pharmaceutical. Propafenone was first approved as Rythmol on 1989-11-27. It is used to treat atrial fibrillation, cardiac arrhythmias, and supraventricular tachycardia in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target potassium voltage-gated channel subfamily A member 5 and beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Propafenone (discontinued: Propafenone, Rythmol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| propafenone | ANDA | 2011-04-13 |
| propafenone hcl | ANDA | 2019-10-09 |
| propafenone hydrochloride | ANDA | 2025-09-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
| cardiac arrhythmias | EFO_0004269 | D001145 | I49.9 |
| supraventricular tachycardia | — | D013617 | I47.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 2 | 7 | 7 | 23 | 39 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | 1 | — | 2 | 2 | 4 | 9 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | 1 | 1 | 3 |
| Ventricular premature complexes | D018879 | — | I49.3 | — | — | — | 2 | 1 | 3 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | 1 | 1 | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | 1 | — | 1 |
| Premature cardiac complexes | D005117 | — | I49.40 | — | — | — | 1 | — | 1 |
| Septic shock | D012772 | — | A48.3 | — | — | — | 1 | — | 1 |
| Shock | D012769 | — | R57.1 | — | — | — | 1 | — | 1 |
| Supraventricular tachycardia | D013617 | — | I47.1 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | 2 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 2 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | 1 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 1 | — | — | 1 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | — | — | 1 |
| Ventricular fibrillation | D014693 | EFO_0004287 | I49.01 | — | — | 1 | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Sick sinus syndrome | D012804 | EFO_0004275 | I49.5 | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Propafenone |
| INN | propafenone |
| Description | Propafenone is an aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. It has a role as an anti-arrhythmia drug. It is a secondary amino compound, a secondary alcohol and an aromatic ketone. It is a conjugate base of a propafenone(1+). |
| Classification | Small molecule |
| Drug class | antiarrhythmics (propafenone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 54063-53-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL631 |
| ChEBI ID | 63619 |
| PubChem CID | 4932 |
| DrugBank | DB01182 |
| UNII ID | 68IQX3T69U (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
KCNA5
KCNA5
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
KCNA5
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily A member 5
Protein synonyms
cardiac potassium channel, HPCN1, insulinoma and islet potassium channel, potassium channel 1, potassium channel, voltage gated shaker related subfamily A, member 5, potassium voltage-gated channel, shaker-related subfamily, member 5, Voltage-gated potassium channel HK2, voltage-gated potassium channel protein Kv1.5, Voltage-gated potassium channel subunit Kv1.5
Uniprot ID
Mouse ortholog
Kcna5 (16493)
potassium voltage-gated channel subfamily A member 5 (Q9Z1R6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Propafenone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,169 documents
View more details
Safety
Black-box Warning
Black-box warning for: Propafenone hcl, Propafenone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,804 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use